UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-A/A

Amendment No. 1

 

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Eyegate Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

     
Delaware   98-0443284

(State of incorporation

or organization)

 

 

(I.R.S. Employer

Identification No.)

 

 

     
271 Waverley Oaks Road
Suite 108
Waltham, Massachusetts
  02452
(Address of principal executive offices)   (Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

     

Title of each class

to be so registered 

 

Name of each exchange on which

each class is to be registered 

Common stock, par value $0.01 per share (“Common Stock”)   The NASDAQ Stock Market LLC
Warrants to purchase Common Stock (“Warrants”)   The NASDAQ Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.  x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.  ¨

Securities Act registration statement file number to which this form relates: 333-204780

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 
 

 

 

This Amendment No. 1 to the Form 8-A filed by Eyegate Pharmaceuticals, Inc. (the “Registrant”) on July 28, 2015 (the “Original Filing”), is being filed to add the Warrants an additional class of security to be registered hereunder. No other changes have been made to the Original Filing.

 

Item 1. Description of Registrant’s Securities to be Registered.

 

The description of the Common Stock and Warrants of the Registrant to be registered hereunder set forth under the caption “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-204780) as originally filed with the Securities and Exchange Commission on June 5, 2015, including any subsequent amendments thereto (the “Form S-1”), and in the prospectus to be filed by the Registrant pursuant to Rule 424(b) of the Securities Act of 1933, as amended, which prospectus will constitute a part of the Form S-1, is hereby incorporated by reference in response to this item.

 

Item 2. Exhibits.

 

Under the instructions as to exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereunder are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 
 

  

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: July 30, 2015

 

       
  EYEGATE PHARMACEUTICALS, INC.
     
  By:   /s/ Stephen From
      Stephen From
      President and Chief Executive Officer